TABLE 2.
Overall incidence of adverse events (AEs)
| Ecleralimab 4 mg (n=15) | Placebo (n=13) | |||
| nE | nS (%) | nE | nS (%) | |
| Total AEs | 51 | 10 (66.7) | 42 | 12 (92.3) |
| AEs of mild intensity | 40 | 10 (66.7) | 30 | 11 (84.6) |
| AEs of moderate intensity | 11 | 6 (40.0) | 12 | 8 (61.5) |
| AEs of severe intensity | 0 | 0 | ||
| Study drug-related AEs | 4 | 4 (26.7) | 0 | |
| Serious AEs | 0 | 0 | ||
| AEs leading to discontinuation of study treatment | 0 | 0 | ||
| Study drug-related AEs leading to discontinuation of study treatment | 0 | 0 | ||
Percentage is based on the number of subjects. Only AEs occurring at or after first drug intake are included. nE: number of AEs in the category; nS: number of subjects with at least one AE in the category.